Bayer AG (OTC:BAYRY) Stock Upgrade
Equity research analysts at the HSBC Securities division of equities hiked shares of Bayer AG (OTC:BAYRY) from a Hold to a Buy on Thursday morning.
Approximately 57,140 shares of stock traded hands. Bayer AG (ADR) (OTC:BAYRY) has declined 13.79% since May 7, 2015 and is downtrending. It has underperformed by 11.86% the S&P500.
Bayer AG is a strategic management holding company. The company has a market cap of $103.82 billion. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 25.78 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.
According to Zacks Investment Research, “Bayer AG, best known for its flagship product, Bayer Aspirin, produces a broad range of health care, crop protection, polymer, and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability, and improve people’s lives.” Get a free copy of the Zacks research report on Bayer AG (ADR) (BAYRY).